Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9BUL9
UPID:
RPP25_HUMAN
Alternative names:
-
Alternative UPACC:
Q9BUL9; D3DW70; Q9NX88
Background:
Ribonuclease P protein subunit p25 plays a crucial role in cellular function as part of the ribonuclease P complex, involved in generating mature tRNA molecules by cleaving their 5'-ends. This protein is also integral to the MRP ribonuclease complex, responsible for pre-rRNA sequence cleavage, highlighting its essential role in RNA processing.
Therapeutic significance:
Understanding the role of Ribonuclease P protein subunit p25 could open doors to potential therapeutic strategies.